No Data
No Data
Recursion, Exscientia Seek Support for Merger Ahead of Special Meeting
Why Recursion Is Getting Love as an AI and Drug Discovery Top Pick
Cathie Wood's ARK Investment Buys 124K Shares of Recursion Pharmaceuticals Today
Cathie Wood's ARK Sheds Robinhood Stock, Adds to Amazon and Coinbase
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12
Recursion Pharmaceuticals' Groundbreaking Cancer Drug Enters Clinical Trials
No Data
No Data